4D Molecular Therapeutics, Inc. (FDMT) — Analyst outlook / Analyst consensus target is. Based on 14 analyst ratings, the consensus is bullish — 10 Buy, 3 Hold, 1 Sell.
The consensus price target is $25.33 (low: $17.00, high: $33.00), representing an upside of 162.2% from the current price $9.66.
Analysts estimate Earnings Per Share (EPS) of $-2.91 and revenue of $0.00B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-2.98 vs est $-2.91 (missed -2.4%). 2025: actual $-2.42 vs est $-3.26 (beat +25.7%). Analyst accuracy: 81%.
FDMT Stock — 12-Month Price Forecast
$25.33
▲ +162.22% Upside
Average Price Target
Based on 14 Wall Street analysts offering 12-month price targets for 4D Molecular Therapeutics, Inc., the average price target is $25.33, with a high forecast of $33.00, and a low forecast of $17.00.
The average price target represents a +162.22% change from the last price of $9.66.
Highest Price Target
$33.00
Average Price Target
$25.33
Lowest Price Target
$17.00
FDMT Analyst Ratings
Buy
Based on 14 analysts giving stock ratings to 4D Molecular Therapeutics, Inc. in the past 3 months
EPS Estimates — FDMT
81%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual –$2.98
vs Est –$2.91
▼ 2.4% off
2025
Actual –$2.42
vs Est –$3.26
▲ 34.7% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.
Revenue Estimates — FDMT
0%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024
Actual $0.000B
vs Est $0.001B
▼ 3,372.4% off
2025
Actual $0.085B
vs Est $0.034B
▲ 60.6% off
Revenue Trend
Revenue has been relatively flat. Analysts forecast revenue contraction ahead.
